scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1049790432 |
P356 | DOI | 10.1038/ONC.2013.497 |
P8608 | Fatcat ID | release_kt2npdofdbaivn42hcfbxciwx4 |
P932 | PMC publication ID | 4876694 |
P698 | PubMed publication ID | 24276248 |
P2093 | author name string | C G Drake | |
P Sharma | |||
W Gerritsen | |||
P2860 | cites work | Global cancer statistics | Q22241238 |
Hallmarks of Cancer: The Next Generation | Q22252312 | ||
Abiraterone in metastatic prostate cancer without previous chemotherapy | Q24612084 | ||
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer | Q24684241 | ||
Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy | Q26851608 | ||
Circulating tumors cells as biomarkers: progress toward biomarker qualification | Q26852579 | ||
Sipuleucel-T immunotherapy for castration-resistant prostate cancer | Q27860648 | ||
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
Cancer despite immunosurveillance: immunoselection and immunosubversion | Q28263865 | ||
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study | Q28275476 | ||
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer | Q29616123 | ||
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 | ||
Increased survival with enzalutamide in prostate cancer after chemotherapy | Q29617511 | ||
Abiraterone and increased survival in metastatic prostate cancer | Q29617512 | ||
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy | Q29619961 | ||
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Q29620155 | ||
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group | Q33566395 | ||
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer | Q33952036 | ||
Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy | Q34149569 | ||
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models | Q34150018 | ||
Novel therapies for metastatic castrate-resistant prostate cancer | Q34249263 | ||
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer | Q34368408 | ||
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer | Q34415510 | ||
Activation of thymic regeneration in mice and humans following androgen blockade | Q34440551 | ||
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer | Q34543188 | ||
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q34620634 | ||
Prostate cancer as a model for tumour immunotherapy | Q34856875 | ||
Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence | Q35076330 | ||
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial | Q83427167 | ||
Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer | Q114738516 | ||
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab | Q35289145 | ||
Castration-resistant prostate cancer: systemic therapy in 2012 | Q35865011 | ||
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma | Q35871798 | ||
Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures | Q36181578 | ||
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps | Q36185518 | ||
The anticancer immune response: indispensable for therapeutic success? | Q36677608 | ||
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study | Q36999978 | ||
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy | Q37193043 | ||
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement | Q37193049 | ||
Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation | Q37268005 | ||
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody | Q37351567 | ||
A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. | Q37418671 | ||
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect | Q37821337 | ||
Contribution of the immune system to the chemotherapeutic response. | Q37832967 | ||
How to improve the immunogenicity of chemotherapy and radiotherapy | Q37836489 | ||
Combining immunotherapy and targeted therapies in cancer treatment | Q37995939 | ||
Melanoma as a model tumour for immuno-oncology | Q38037486 | ||
Immunohistochemistry in the era of personalised medicine | Q38045874 | ||
Identification of docetaxel resistance genes in castration-resistant prostate cancer | Q39452736 | ||
Increased expression of class III beta-tubulin in castration-resistant human prostate cancer | Q39811005 | ||
Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy | Q39829746 | ||
Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade | Q39894616 | ||
Radiotherapy augments the immune response to prostate cancer in a time-dependent manner | Q40080152 | ||
Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor | Q40412166 | ||
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing | Q40543778 | ||
The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development | Q41915850 | ||
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer | Q42032055 | ||
Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapy | Q42180889 | ||
Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. | Q42927772 | ||
Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma | Q44080958 | ||
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors | Q44542342 | ||
The role of immunotherapy in prostate cancer: an overview of current approaches in development. | Q44947041 | ||
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study | Q46817220 | ||
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. | Q50966333 | ||
Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. | Q53099425 | ||
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer | Q56903097 | ||
Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice | Q56907375 | ||
Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer | Q60156266 | ||
Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer | Q60368025 | ||
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy | Q73496463 | ||
Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection | Q80284129 | ||
Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse | Q81999205 | ||
P433 | issue | 43 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | prostate cancer | Q181257 |
immunotherapy | Q1427096 | ||
P304 | page(s) | 5053-64 | |
P577 | publication date | 2014-10-23 | |
P1433 | published in | Oncogene | Q1568657 |
P1476 | title | Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy | |
P478 | volume | 33 |
Q96353886 | A Multimodal Theranostic Nanoformulation that Dramatically Enhances Docetaxel Efficacy Against Castration Resistant Prostate Cancer |
Q98947294 | ACK1-AR and AR-HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers |
Q36782633 | Adipocytes promote prostate cancer stem cell self-renewal through amplification of the cholecystokinin autocrine loop |
Q37709535 | Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles |
Q41573500 | Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer |
Q37390666 | Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer |
Q64113560 | Combination of the natural product capsaicin and docetaxel synergistically kills human prostate cancer cells through the metabolic regulator AMP-activated kinase |
Q38364647 | Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer |
Q47307286 | Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy. |
Q36433756 | Diagnosis of prostatic carcinoma on multiparametric magnetic resonance imaging using shearlet transform |
Q48176349 | Immunotherapy for Prostate Cancer: Where We Are Headed |
Q42022308 | MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling |
Q39333529 | Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies. |
Q37718328 | Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways |
Q39340541 | Personalized peptide vaccines and their relation to other therapies in urological cancer |
Q47757361 | Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells |
Q41858027 | SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing |
Q28251240 | Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer |
Q33821011 | Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells |
Search more.